Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Deferred Taxes: 2014-2025

Historic Deferred Taxes for Ani Pharmaceuticals (ANIP) over the last 11 years, with Sep 2025 value amounting to $18.8 million.

  • Ani Pharmaceuticals' Deferred Taxes rose 436.44% to $18.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.6 million, marking a year-over-year increase of 55.62%. This contributed to the annual value of -$21.9 million for FY2024, which is 86.65% down from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Deferred Taxes is $18.8 million, which was up 631.67% from -$3.5 million recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Deferred Taxes peaked at $18.8 million during Q3 2025, and registered a low of -$17.5 million during Q4 2024.
  • For the 3-year period, Ani Pharmaceuticals' Deferred Taxes averaged around -$2.0 million, with its median value being -$3.3 million (2023).
  • Per our database at Business Quant, Ani Pharmaceuticals' Deferred Taxes crashed by 2,575.27% in 2022 and then skyrocketed by 436.44% in 2025.
  • Ani Pharmaceuticals' Deferred Taxes (Quarterly) stood at -$8.1 million in 2021, then soared by 79.91% to -$1.6 million in 2022, then plummeted by 413.60% to -$8.3 million in 2023, then slumped by 110.04% to -$17.5 million in 2024, then surged by 436.44% to $18.8 million in 2025.
  • Its Deferred Taxes stands at $18.8 million for Q3 2025, versus -$3.5 million for Q2 2025 and -$3.4 million for Q1 2025.